Top Markets
#1 ADO Protocol ADO Protocol +193.44%
#2 Islamic Coin Islamic Coin +155.40%
#3 GoPlus Security GoPlus Security +43.47%
#4 GAIB AID GAIB AID +24.67%
#5 Casper Network Casper Network +15.03%
#6 Verus Coin Verus Coin +13.64%
#7 SkyAI SkyAI +13.54%
#8 Starpower Starpower +12.35%
#9 o1.exchange o1.exchange +11.59%
#10 Ontology Gas Ontology Gas +10.82%
Coin of the day
ADO Protocol ADO Protocol
Settings
Language
ENGLISH
Currency
USD
Theme
NeoImmuneTech, Inc. NeoImmuneTech, Inc.

NeoImmuneTech, Inc.

950220
Rank in Stocks #33498
As a clinical-stage biotechnology firm with a strong focus on T cells,... As a clinical-stage biotechnology firm with a strong focus on T cells, NeoImmuneTech, Inc. is dedicated to creating and marketing innovative immunotherapies. The company's lead product, NT-I7, is a long-acting human IL-7 currently in clinical development for its potential to treat a range of oncologic and infectious conditions. Founded in 2014, NeoImmuneTech is based in Rockville, Maryland.
Share Price
$1.12
Last synced: 2026-08-14
Market Cap
$7.52M
Change (1 day)
4.51%
Change (1 year)
-94.79%
Country
US
Trade NeoImmuneTech, Inc. (950220)

Category

Healthcare
P/B ratio for NeoImmuneTech, Inc. (950220)
P/B ratio as of 2026 TTM: 0
According to NeoImmuneTech, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for NeoImmuneTech, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE